Nocimed is pleased to announce that its scientific abstract entitled "Non-invasive In-vivo MR Spectroscopy of Non-herniated versus Herniated Painful Lumbar Discs" has been accepted and awarded as one of the 16 “Best Papers” from several hundred abstract submissions for oral podium presentation at the International Society for the Advancement of Spine Surgery (ISASS) 2013 annual conference being held April 3-5, 2013 in Vancouver, Canada. This paper presents certain clinical MR spectroscopy results from data that was non-invasively acquired in vivo from non-herniated painful, herniated painful, and non-painful lumbar discs, and subsequently post-processed and evaluated, via the company’s investigational Nociscan Virtual Discogram diagnostic platform. The investigational Nociscan MRS exams were conducted immediately following standard lumbar MRI via a commercial Siemens 3T Verio MR scanner and single voxel spectroscopy pulse sequence, using a custom acquisition protocol developed by Nocimed and under a Nocimed-sponsored IRB-approved clinical research study at The Orthopedic Center of St. Louis (TOCSL). The podium presentation is scheduled to be delivered by Matt Gornet, MD, a named co-author under the awarded paper and Principal Investigator for the clinical Nociscan investigations at TOCSL.

About Nociscan™ Virtual Discogram™ and Sigpro™

The Nociscan Virtual Discogram is an investigational spine diagnostic platform, and is a new application of MR spectroscopy (MRS) to non-invasively measure disc chemistry as a brief adjunct to standard MRI exams. The Nociscan exam is performed by acquiring an MRS spectrum from a disc nucleus using commercial MR scanners and MRS pulse sequences already indicated for tissue chemistry assessment, but using a proprietary procedural protocol being evaluated specifically for disc spectroscopy. The raw acquired MRS data is then uploaded electronically, via a secure web interface, to a proprietary “cloud”-based Sigpro MRS signal post-processor. Sigpro automatically provides a final post-processed spectrum for making quantitative measurements at spectral peaks associated with certain chemicals. These chemical signatures for the disc may then be assessed as potential chemical biomarkers for correlation to disc pathologies such as degeneration and pain. The investigational Nociscan Virtual Discogram was previously awarded "#1 Overall Best New Technology in Spine Care for 2011" by Orthopedics This Week at the North American Spine Society 2011 annual meeting in November, 2011.

About Nocimed™, LLC

Nocimed, LLC’s mission is to provide disruptive new medical diagnostic platform technologies to address significant areas of unmet need in substantial clinical and research markets. The Company’s primary emphasis is to deliver this via web or “cloud”-based Software-as-a-Service (SaaS) solutions, principally for diagnostic imaging post-processing. The Company is initially developing these solutions for musculoskeletal and pain indications – with initial focus on discogenic low back pain, a leading reported cause of worker’s compensation and disability claims and patient-doctor visits for middle-aged adults. Nocimed was founded in 2008 as a Delaware Limited Liability Company, with its principal place of business in Redwood City, CA, and is privately funded by qualified accredited investors. Further information may be found at www.nocimed.com. Any inquiries may be directed by phone to (650)241-1727, or by email to cwakeman@nocimed.com.

Nociscan Virtual Discogram, Sigpro, and other products and technologies embody exclusive proprietary rights of Nocimed, LLC, including under certain copyrights and granted patents and pending patent applications in the United States and other territories. Nocimed™, Nociscan™, Virtual Discogram™, Nocigram™, Sigpro™, and Autovox™ are proprietary trademarks of Nocimed, LLC. All rights reserved.

CAUTION: Investigational device. Limited by Federal Law to investigational use only.